Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Oct 4;17:86. doi: 10.1186/s12935-017-0457-z

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s) 2017

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

PMC Copyright notice

Fig. 1 — Vemurafenib partially inhibits cell proliferation, cell cycle progression and ERK signaling in BRAF V600E thyroid carcinoma cell lines. a, b Growth rate (a) and cell viability (b) in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells treated with 1 and 10 μM PLX4032. c Cell cycle distribution in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells exposed to 10 μM PLX4032 for 15 h. a–c Statistical significance respect to each untreated control: *p < 0.05; **p < 0.005; ***p < 0.0005. d ERK and phosphoERK immunoblot analysis in BRAF V600E BHT101, FRO and BCPAP thyroid carcinoma cell lines and BRAF-wild type WRO cells exposed to 10 μM PLX4032 for 1 h